Cancer BiologyBlood NeoplasiaPeer-reviewed
EZH2-driven immune evasion at disease presentation defines atargetable high-risk subset of acute leukemia exemplified byt(16;21) FUS::ERG AML
Nathaniel J. Buteyn, Samantha J LaMantia, Connor G Burke…·Timothy Junius Triche
This paper identifies an EZH2-driven immune evasion phenotype in FUS::ERG AML that is reversible with tazemetostat, offering a potential targeted therapy for high-risk acute leukemia.
6 citationstop 1%